Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597640 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL597636 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL597805 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL598502 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL598906 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL598586 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL607721 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL598137 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL599105 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS | |
| SCHEMBL598387 | 1.00 | CYP1A2 (0.76) | CYP1A2SIGMAR1EPHX1ALDH1A1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067164-B1 | Phase change thermal interface material | SAINT GOBAIN PERFORMANCE PLAST (US) | 2004-06-09 | — | — | EP | claimed |
| US-10201879-B2 | Silver paste composition and semiconductor device using same | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| CN-104584140-B | Silver paste composition and semiconductor device using same | 日立化成株式会社 | 2018-01-02 | — | — | CN | disclosed |
| EP-2894641-B1 | SILVER PASTE COMPOSITION AND SEMICONDUCTOR DEVICE USING SAME | HITACHI CHEMICAL CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-20150217411-A1 | SILVER PASTE COMPOSITION AND SEMICONDUCTOR DEVICE USING SAME | RESONAC CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| EP-2894641-A1 | SILVER PASTE COMPOSITION AND SEMICONDUCTOR DEVICE USING SAME | Hitachi Chemical Company, Ltd. (JP) | 2015-07-15 | — | — | EP | disclosed |
| CN-104584140-A | Silver paste composition and semiconductor device using same | HITACHI CHEMICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885SIGMAR1 2761/4885EPHX1 1843/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP1A2 1415/4885SIGMAR1 2979/4885EPHX1 1827/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP1A2 810/4885SIGMAR1 3971/4885EPHX1 272/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CYP1A2 1161/4885SIGMAR1 3639/4885EPHX1 1541/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885SIGMAR1 2820/4885EPHX1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.